This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Patten, S B Articles by Metz, L M Search for Related Content PubMed PubMed Citation Articles by Patten, S B Articles by Metz, L M Social Bookmarking                   What's this?

Interferon ß-1a and depression in relapsing - remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial

Department of Community Health Sciences, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1, Department of Psychiatry, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1

L M Metz

Department of Clinical Neurosciences, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1, University of Calgary MS Clinic, Foothills Medical Centre, 1403-29 Street NW, Calgary, Alberta, Canada T2N 2T9

Depression is a suspected side effect of multiple sclerosis (MS) treatment with interferon ß-1a. However, this has not been confirmed by rigorous studies. Several psychological symptom rating scales were completed during the PRISMS clinical trial of subcutaneous interferon ß-1a (Rebif®) for relapsing - remitting MS. We conducted an analysis of these data in order to determine whether symptom elevations were associated with treatment. The PRISMS clinical trial included 560 subjects from 22 centres in nine countries. There were two active treatment arms (44 mcg x 3 and 22 mcg x 3 subcutaneously three times per week) and a placebo group. Two hundred and sixty-seven of these subjects were enrolled at English speaking study centres, where psychiatric symptom ratings were obtained at baseline, 6, 12, 18 and 24 months using the Center for Epidemiological Studies Depression Rating Scale (CES-D), the General Health Questionnaire (GHQ) and the Beck Hopelessness Scale (BHS). After randomization, the groups completing these scales were similar in terms of age, gender, EDSS, duration of illness and employment status. Median CES-D scores in the high dose, low dose and placebo groups at baseline were also similar: 8.0, 7.0 and 8.0, respectively. After 6 months of treatment, the median change in CES-D score was zero in all three groups. The proportion of subjects exceeding the traditional CES-D cut-point for clinically significant depression (>15) after 6 months of treatment was strongly associated with pre-treatment depression (RR 2.9, 95% C.I.: 1.8 - 4.7), but not with treatment group (chi-square=1.64, d.f.=2, P=0.44). The results were comparable at 12, 18 and 24 months and when ratings from the other scales were evaluated. This analysis confirms that depression is common in persons with MS: the incidence of CES-D depression in the first 6 months of follow-up was 15.6%. However, no evidence of increased depressive symptomatology was observed in association with interferon b-1a (Rebif®).

Key Words: multiple sclerosis • depression • depressive symptoms • depressive disorders - chemically induced • substance-induced mood disorder

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Patten, J. Williams, and L. Metz Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis Multiple Sclerosis, April 1, 2008; 14(3): 406 - 411. [Abstract] [PDF]

				S. Kern and T. Ziemssen Review: Brain immune communication psychoneuroimmunology of multiple sclerosis Multiple Sclerosis, January 1, 2008; 14(1): 6 - 21. [Abstract] [PDF]

				H. J. Kang, D. H. Adams, A. Simen, B. B. Simen, G. Rajkowska, C. A. Stockmeier, J. C. Overholser, H. Y. Meltzer, G. J. Jurjus, L. C. Konick, et al. Gene Expression Profiling in Postmortem Prefrontal Cortex of Major Depressive Disorder J. Neurosci., November 28, 2007; 27(48): 13329 - 13340. [Abstract] [Full Text] [PDF]

				J Porcel, J Rio, A Sanchez-Betancourt, M J Arevalo, M Tintore, N Tellez, C Borras, C Nos, and X Montalban Long-term emotional state of multiple sclerosis patients treated with interferon beta Multiple Sclerosis, November 1, 2006; 12(6): 802 - 807. [Abstract] [PDF]

				P A Arnett and J J Randolph Longitudinal course of depression symptoms in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, May 1, 2006; 77(5): 606 - 610. [Abstract] [Full Text] [PDF]

				R. Pandya, L. Metz, and S. B. Patten Predictive Value of the CES-D in Detecting Depression Among Candidates for Disease-Modifying Multiple Sclerosis Treatment Psychosomatics, April 1, 2005; 46(2): 131 - 134. [Abstract] [Full Text] [PDF]

				R J Siegert and D A Abernethy Depression in multiple sclerosis: a review J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 469 - 475. [Abstract] [Full Text] [PDF]

				S. B Patten, G. Francis, L. M Metz, M. Lopez-Bresnahan, P. Chang, and F. Curtin The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 175 - 181. [Abstract] [PDF]

				S. B Patten, S. Fridhandler, C. A Beck, and L. M Metz Depressive symptoms in a treated multiple sclerosis cohort Multiple Sclerosis, December 1, 2003; 9(6): 616 - 620. [Abstract] [PDF]

				H. Zephir, J. De Seze, T. Stojkovic, B. Delisse, D. Ferriby, M. Cabaret, and P. Vermersch Multiple sclerosis and depression: influence of interferon b therapy Multiple Sclerosis, June 1, 2003; 9(3): 284 - 288. [Abstract] [PDF]

				S Di Legge, M C Piattella, C Pozzilli, P Pantano, F Caramia, I F Pestalozza, A Paolillo, and G L Lenzi Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis Multiple Sclerosis, June 1, 2003; 9(3): 302 - 306. [Abstract] [PDF]